Grace Therapeutics, Inc. (GRCE)

NCM – Цена в реальном времени. Валюта: USD

2.33

-0.02 (-0.85%)

При закрытии: May 12, 2026, 4:00 PM EDT

2.33

0.00 (0.00%)

До открытия: May 13, 2026, 8:46 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Grace Therapeutics, Inc. (GRCE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug

US FDA declines to approve Grace Therapeutics' drug for a type of stroke

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Видео

No Data

Пресс-релизы

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Search stocks

Grace Therapeutics, Inc. (GRCE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug

US FDA declines to approve Grace Therapeutics' drug for a type of stroke

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update

Видео

No Data

Пресс-релизы

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update